Terms: = Liver cancer AND BLM, MGC131620, 641, ENSG00000197299, MGC131618, RECQ2, RECQL2, RECQL3, MGC126616, BS AND Treatment
90 results:
1. [Successful Continuation of treatment in Advanced Colorectal cancer by Switching to a Prior Biologic Agent after Emergence of Bevacizumab Allergy to a Biosimilar Drug-A Case Report].
Ushigome M; Funahashi K; Yoshida K; Okubo K; Miura Y; Suzuki T; Kagami S; Nagashima Y; Koda T; Kaneko T; Kurihara A; Mitsuda A
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1603-1605. PubMed ID: 38303355
[TBL] [Abstract] [Full Text] [Related]
2. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Zeng Q; Klein C; Caruso S; Maille P; Allende DS; Mínguez B; Iavarone M; Ningarhari M; Casadei-Gardini A; Pedica F; Rimini M; Perbellini R; Boulagnon-Rombi C; Heurgué A; Maggioni M; Rela M; Vij M; Baulande S; Legoix P; Lameiras S; ; Bruges L; Gnemmi V; Nault JC; Campani C; Rhee H; Park YN; Iñarrairaegui M; Garcia-Porrero G; Argemi J; Sangro B; D'Alessio A; Scheiner B; Pinato DJ; Pinter M; Paradis V; Beaufrère A; Peter S; Rimassa L; Di Tommaso L; Vogel A; Michalak S; Boursier J; Loménie N; Ziol M; Calderaro J
Lancet Oncol; 2023 Dec; 24(12):1411-1422. PubMed ID: 37951222
[TBL] [Abstract] [Full Text] [Related]
3. Clinical manifestation, staging and prognosis of hepatocellular carcinoma in Gambian patients.
Bittaye SO; Kambi A; Tekanyi MAI; Tamba S; Sanneh L; Sisawo MM; Jatta A; Fatty G; Jeng A; Jallow MS; Leigh O; Njie R
BMC Gastroenterol; 2023 Sep; 23(1):321. PubMed ID: 37730538
[TBL] [Abstract] [Full Text] [Related]
4. Nomograms for predicting overall survival in colorectal cancer patients with metastasis to the liver, lung, bone, and brain.
Wang H; Shan X; Zhang M; Qian K; Shen Z; Zhou W
Cancer Causes Control; 2023 Dec; 34(12):1059-1072. PubMed ID: 37486401
[TBL] [Abstract] [Full Text] [Related]
5. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis.
Liu H; Han CL; Tian BW; Ding ZN; Yang YF; Ma YL; Yang CC; Meng GX; Xue JS; Wang DX; Dong ZR; Chen ZQ; Hong JG; Li T
Expert Rev Gastroenterol Hepatol; 2023; 17(6):623-633. PubMed ID: 37148261
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.
Han CL; Tian BW; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Tan SY; Dong ZR; Yan YC; Hong JG; Chen ZQ; Wang DX; Li T
Cancer Immunol Immunother; 2023 Jul; 72(7):1957-1969. PubMed ID: 36811662
[TBL] [Abstract] [Full Text] [Related]
7. Changes in breast cancer staging trends among Egyptian women after COVID-19: A retrospective single-center study.
Abd El Wahab MH; Ibrahim AH; Gado O; Bahbah AM; Fadlalla W; Fakhry S; Mamdouh MM; Kamel MM; Moaz I; Rabea A; Helal AM
Int J Immunopathol Pharmacol; 2023; 37():3946320231152835. PubMed ID: 36649477
[TBL] [Abstract] [Full Text] [Related]
8. Intra-tumor heterogeneity and prognostic risk signature for hepatocellular carcinoma based on single-cell analysis.
Liu C; Pu M; Ma Y; Wang C; Kong L; Zhang S; Zhao X; Lian X
Exp Biol Med (Maywood); 2022 Oct; 247(19):1741-1751. PubMed ID: 36330895
[TBL] [Abstract] [Full Text] [Related]
9. Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma.
Xiao Y; Zhang B; Cloyd JM; Xu G; Du S; Mao Y; Pawlik TM
Surg Oncol; 2022 Sep; 44():101849. PubMed ID: 36116415
[TBL] [Abstract] [Full Text] [Related]
10. Chemotherapy in patients with a solitary colorectal liver metastasis - A nationwide propensity score matched study.
Frühling P; Urdzik J; Isaksson B
Eur J Surg Oncol; 2022 Oct; 48(10):2188-2194. PubMed ID: 35672233
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Characteristics of T Cell-Mediated Tumor Killing in Hepatocellular Carcinoma.
Hong WF; Liu MY; Liang L; Zhang Y; Li ZJ; Han K; Du SS; Chen YJ; Ma LH
Front Immunol; 2022; 13():868480. PubMed ID: 35572523
[TBL] [Abstract] [Full Text] [Related]
12. Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.
Hjorth CF; Damkier P; Stage TB; Feddersen S; Hamilton-Dutoit S; Rørth M; Ejlertsen B; Lash TL; Ahern TP; Sørensen HT; Cronin-Fenton D
Breast Cancer Res Treat; 2022 Jul; 194(2):353-363. PubMed ID: 35501422
[TBL] [Abstract] [Full Text] [Related]
13. Portal vein embolization via the ipsilateral percutaneous transhepatic approach versus laparotomic transileocecal approach: complications, profile and changes in future liver remnant volume.
Okada M; Ihara K; Miyoshi K; Nakao S; Tanabe M; Tokumitsu Y; Harada E; Sakamoto K; Nagano H; Ito K
Br J Radiol; 2022 Jul; 95(1135):20210854. PubMed ID: 35348358
[TBL] [Abstract] [Full Text] [Related]
14. Prostate arterial chemoembolization for treatment of refractory hematuria and urinary retention in patients with localized advanced prostate cancer.
Wang MQ; Zhang JL; Duan F; Yuan B; Xin H; Fu JX; Ye HY; Yu HK; Feng DP; Cheng K; Zhang XJ
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):88-95. PubMed ID: 35249108
[TBL] [Abstract] [Full Text] [Related]
15. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study.
Shen J; Shen H; Ke L; Chen J; Dang X; Liu B; Hua Y
Front Immunol; 2022; 13():815575. PubMed ID: 35173728
[TBL] [Abstract] [Full Text] [Related]
16. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients.
Lee S; Jung J; Park JH; Kim SY; Choi J; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Park HH; Kim JH; Yoon SM
BMC Cancer; 2022 Feb; 22(1):175. PubMed ID: 35172769
[TBL] [Abstract] [Full Text] [Related]
17. Management and Survival Analysis of Gastrointestinal Neuroendocrine Tumors by Different Tumor Characteristics: Tertiary Center Experience.
Gonulal B; Bilgic Y; Akbulut S; Karabulut E; Samdanci ET
J Gastrointest Cancer; 2022 Dec; 53(4):915-920. PubMed ID: 34524616
[TBL] [Abstract] [Full Text] [Related]
18. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line treatment in Patients With Advanced Gallbladder cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT).
Ramaswamy A; Ostwal V; Sharma A; Bhargava P; Srinivas S; Goel M; Patkar S; Mandavkar S; Jadhav P; Parulekar M; Choudhari A; Gupta S
JAMA Oncol; 2021 Mar; 7(3):436-439. PubMed ID: 33270098
[TBL] [Abstract] [Full Text] [Related]
20. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
[TBL] [Abstract] [Full Text] [Related]
[Next]
